In response to a query on the limitations of presenting changes in drug treatment as percentage changes in levodopa equivalents, as shown in Table 1 of our article, we would like to submit further supplementary information detailing the actual drug changes during the course of this phase 1 clinical study. This information would allow for a better clinical interpretation of the participants, who showed both significant off-and on-medication benefit. Accordingly, we have tabulated the drug and levodopa equivalent changes up to 24 months, beyond the 12-month clinical data and 18-month positron emission tomography data presented in our article. 
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